The Uromigos

Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya

Laurence Albiges discusses biomarker studies, new combinations and new therapies which were covered in the KCRS23 meeting in the ‘new studies' session.

A look forward to bladder, kidney and prostate cancer sessions at ASCO 2023

Josh Meeks describes his teams Nature Communications paper (including 11 supplementary figures).

Tom, who failed to invite a guest, quizzes Brian on the new data from the meeting he attended.

Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC classification for renal cell carcinoma and the treatment of patients with favorable risk disease. Dr. Heng is a professor of oncology at the University of Calgary in Alberta, Canada, and is the leader of the International mRCC Database Consortium (IMDC) which consists of data from over 9,200 patients with mRCC treated with targeted therapies from over 38 cancer centers worldwide.

In the first part of our Hollywood tour, Amar Kishan, MD, joins us to discuss his recent meta-analysis published in the Journal of Clinical Oncology on the effects of concurrent adjuvant sequencing versus neoadjuvant concurrent sequencing. Dr. Kishan also gives an overview of the added benefit that androgen deprivation therapy provides when combined with radiation therapy. Dr. Kishan is the Vice Chair of Clinical and Translational Research and Chief of GU Radiotherapy at the University of California, Los Angeles.

We’re joined by Toni Choueiri, MD, and Brian Shuch, MD, to discuss several studies on the use of belzutifan alone and in combination with other treatments in patients with early and late-stage renal cancer, as well as patients with Von Hippel-Lindau syndrome and advanced sporadic RCC. Dr. Shuch is the director of the University of California, Los Angeles’s Kidney Cancer Program and is the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research. Dr. Choueiri is the director of Dana-Farber Cancer Institute’s Lank Center for Genitourinary Oncology, and serves as medical director of Dana-Farber’s International Strategic Initiatives.

Ursula Vogl, MD, discusses her career in the prostate cancer and renal cell cancer fields, as well as recent projects that she has contributed to including a prostate cancer investigator-led trial on patients with PSA-only progression. Dr. Vogl is a senior physician oncologist at the Istituto Oncologico della Svizzera Italiana in Switzerland, and is the clinical head of the Prostate Cancer Center of Southern Switzerland.

Sia Daneshmand, MD, joins the show to review 2 studies on the use of erdafitinib for the treatment of non-muscle invasive bladder cancer, including the THOR-2 trial investigating erdafitinib versus intravesical chemotherapy in patients who received BCG therapy and recurred with high-risk NMIBC. Dr. Daneshmand is the director of urologic oncology at the Keck School of Medicine, University of Southern California, Los Angeles.

Kala Sridhar, MD discusses her recent work on the PET MUSE study on the impact of PET imaging in muscle-invasive urothelial carcinoma, as well as a neoadjuvant sub-study. Dr. Sridhar is a Genitourinary Medical Oncologist at the Princess Margaret Cancer Center in Toronto, and a Professor in the Department of Medicine at the University of Toronto.

Karine Tawagi, MD, Assistant Professor of Clinical Medicine and Associate Fellowship Program Director at the University of Illinois in Chicago, joins us for a new episode of their Rising Star series. Dr. Tawagi discusses her work in immune-related toxicities, and her focus on bladder,

Michiel Van der Heijden, MD, PhD, joined Tus to review bladder cancer presentations from the 2023 ASCO GU Cancers Symposium, including the phase 1B NABUCCO trial on the use of high- or low-dose preoperative ipilimumab with nivolumab for stage III urothelial cancer, as well as his paper on the use of predictive biomarkers for survival benefit with ramucirumab in the RANGE trial. Dr. Van der Heijden is a medical oncologist research group leader at The Netherlands Cancer Institute, focusing on the improvement of bladder cancer treatment.

The Uromigos are joined by Daniel George, MD, to review RCC and prostate cancer presentations from the 2023 ASCO GU Cancers Symposium, including triplet versus doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Dr. George is a medical oncologist at Duke Health, specializing in genitourinary malignancies.

Brian Shuch, MD, discusses the ZIRCON Phase III kidney cancer imaging study to determine the identification and characterization abilities of TLX250-CDx for clear cell renal cell carcinoma that was presented at the 2023 ASCO GU Cancers Symposium. Dr. Shuch is the Director of the University of California, Los Angeles Kidney Cancer Program, and an Associate Professor of Urology.

The Uromigos are joined by Christian Kollmannsberger, MD, FRCPC, to discuss his presentation at the ASCO GU Cancers Symposium on utilizing miR371 as a biomarker for germ cell tumors to help optimize patient management by improving decision-making. Dr. Kollmannsberger is a medical oncologist at the British Columbia Cancer Agency Vancouver Cancer Centre, and Clinical Professor at the University of British Columbia.

The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembrolizumab monotherapy for patients with high-risk non-muscle-invasive bladder cancer who are unresponsive to bacillus Calmette–Guérin therapy. Dr. Necchi is an Associate Professor at Università Vita-Salute San Raffaele, Head of Genitourinary Medical Oncology at Ospedale San Raffaele, and Vice President of the Global Society of Rare GU Tumors.

Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the phase 3 IMvigor130 study that examined 3 treatments for patients with metastatic urothelial carcinoma: chemotherapy, single-agent atezolizumab, or a combination treatment of atezolizumab plus chemotherapy. Dr. Grande is Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center Madrid.

Matt Galsky, MD discusses several abstracts presented at the 2023 ASCO GU Cancers Symposium on perioperative nivolumab for urothelial cancer, including an update on the CheckMate 274 trial that examined adjuvant nivolumab versus placebo in patients with high-risk muscle invasive urothelial cancer after radical surgery. Dr. Galsky is the Director of Genitourinary Medical Oncology at The Tisch Cancer Institute and Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

The Uromigos met with Michael Morris, MD while at the 2023 ASCO GU Cancers Symposium to discuss PARP inhibition for castration-resistant prostate cancer and the differing opinions on how and when it should be utilized. Dr. Morris is a prostate cancer specialist and researcher, and the Prostate Cancer Section Head at Memorial Sloan Kettering Cancer Center.

Neeraj Agarwal, MD, FASCO, describes the data from the TALAPRO-2 study on combination talazoparib and enzalutamide for metastatic castration-resistant prostate cancer as presented at the 2023 ASCO GU Cancers Symposium. Dr. Agarwal is a medical oncologist and Presidential Endowed Chair at Huntsman Cancer Institute, as well as editor-in-chief for ASCO Daily News.

The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, Senior Physician at the Davidoff Cancer Center of Rabin Medical Center. Dr. Goldstein specializes in the treatment of prostate, bladder, kidney and testicular cancers.

Petros Grivas, MD, PhD joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the results of the drug's EV-301 trial. The combination treatment of EV and pembrolizumab versus chemotherapy alone is also discussed, including the EV-302 trial. Dr. Grivas is a professor in the Division of Medical Oncology at the University of Washington School of Medicine, as well as a physician at Fred Hutch Cancer Center.